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Abstract 
Three decades after the discovery of prions as the cause of Creutzfeldt-Jakob disease and 
other transmissible spongiform encephalopathies, we are still nowhere close to finding an 
effective therapy. Numerous pharmacological interventions have attempted to target various 
stages of disease progression, yet none has significantly ameliorated the course of disease. 
We still lack a mechanistic understanding of how the prions damage the brain, and this 
situation results in a dearth of validated pharmacological targets. In this review, we discuss 
the attempts to interfere with the replication of prions and to enhance their clearance. We 
also trace some of the possibilities to identify novel targets that may arise with increasing 
insights into prion biology.  
 
Prions and prion diseases 
Prion diseases, or transmissible spongiform encephalopathies (TSEs), are caused by the 
ordered aggregation of PrPSc, a misfolded version of the cellular prion protein PrPC. Because 
similar mechanisms are operative in many other neurodegenerative and systemic diseases, 
the protein aggregates causing the latter were termed “prionoids” (1; 2). By our definition, 
prionoids operate similarly to prions at the molecular level, but have not (yet) been shown to 
be transmissible from one individual to another. In the case of prion disease, the aggregation 
is self-sustaining and therefore transmissible between individuals – which renders TSEs 
infectious (3-6). These diseases comprise Creutzfeldt-Jakob disease, Kuru, Fatal Familial 
Insomnia  and genetic TSEs in humans (7); the latter are caused by mutations in the PRNP 
gene encoding PrPC. Neuropathologically, nonspecific signs (astrogliosis, neuronal loss, 
amyloid deposition) are accompanied by “spongiform” changes; intraneuronal and 
intraneuritic vacuoles occasionally containing degenerating organelles (8). The spongiform 
degeneration of neurons is highly specific to prion diseases and typically allows for a 
definitive diagnosis.  
The presence of cellular prion protein is not only necessary for the de novo generation of 
prions, but also for the host organism to experience prion-related neurotoxicity (9). Mice 
ablated for PrPC do not acquire the disease after exposure to prions. The availability of PrPC 
seems to be rate-limiting, as prion-infected mice containing only single allele of the Prnp 
gene encoding PrPC develop the disease much later than wild-type mice.  
Prion diseases are rare, with 1.5-2 reported cases per million people per year. Yet they are 
invariably fatal, and currently there is no effective treatment. Identification of any potential 
anti prion therapy could also pave way for treatment of misfolding disorders induced by 
prionoids. Here we focus on the therapeutics that in our opinion may have the potential to 
succeed and on the challenges awaiting them. 
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Targeting prion conversion  
The cellular PrPC is expressed on the plasma membrane, where it is sorted into detergent 
resistant membrane domain (10). The presence of certain mutations may induce PrPC to 
adopt, through poorly understood mechanisms, a pathological and ultimately infectious 
conformation leading to disease (11). Ordered PrPSc aggregates can seed the nucleation of 
further prions. PrPSc can assume a broad range of compositions ranging from large insoluble 
aggregates and plaques to small oligomers (6).  
Polyanionic compounds and amyloidotropic dyes can abrogate the conversion of PrPC to 
PrPSc in vitro (12; 13), but could not be translated into therapies due to toxicity, poor 
pharmacokinetics and low efficacy (14; 15). Treatment of prion-infected neuroblastoma cells 
with branched polyamines resulted in clearance of PrPSc (16). There compounds are 
protonated at acidic pH and may act on prion conversion in endosomes and lysosomes (16). 
However, none of these compounds had any beneficial effect in vivo.  
Dendrimers are synthetic molecules composed mainly of branched polyamines that with 
modifiable end groups (17). Phosphorous dendrimers were effective anti-prion agents in vitro 
and significantly cleared PrPSc, yet were not developed further (18). Pentosan polysulfate 
(PPS) prolonged the survival of prion-infected mice and was thought to interfere with the 
conversion of PrPC to PrPSc, but did not have any reproducible effect in prion-affected 
humans (19; 20). Amantadine, originally used prophylactically against influenza virus was 
suggested to have ameliorated the clinical course of CJD in a variety of reports with 
anecdotal survival times of up to several years after first symptoms have occurred (21). 
Other reports however failed to reproduce beneficial effects of amantadine in CJD patients 
(22; 23). Another antiviral drug, acyclovir, was ineffective in two patients suffering from CJD 
(24; 25) as was interferon in a case series of two patients (26). Flupirtine, an aminopyridine 
commonly used as analgetic, was used in a placebo-controlled, double-blind study that 
suggested amelioration of cognitive deficits in sCJD and gCJD despite of unchanged survival 
times (27).  
Quinacrine is an antiprotozoal drug that was approved in the 1930s as an antimalarial agent 
and - at the vCJD epidemic at the last turn of the millennial - the lack of efficient anti-prion 
compounds urged researchers to recruit patients for clinical studies (28). An open 
compassionate trial of quinacrine in 30 sCJD and two vCJD patients did not significantly 
prolong the survival or ameliorate the functional impairments and neither did it show 
beneficial effects on brain pathology (29). PRION-1, a prospective, patient-preference trial of 
quinacrine also failed to significantly prolong the survival or improve cognitive deficits in the 
107 patients enrolled (30). The study conductors hypothesized that low levels of the drug in 
the cerebrospinal fluid may be responsible for the failure to reach clinical endpoints, although 
application of the drug showed an overall acceptable safety profile (30). Since 
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compassionate-use trials cannot detect small effects of a molecule due to the lack of a 
placebo arm, a randomized, double-blind, placebo-controlled trial of quinacrine in sCJD 
patients was performed thereafter (31). 51 patients were eventually included for functional 
and survival analyses. Although patients in the quinacrine arm performed slightly better in 
terms of functional scores during the early treatment course, no survival benefit was 
observed upon quinacrine administration, leading to its elimination as a prion disease 
therapeutic (31). 
We have reported the generation of reactive oxygen species to be a downstream effector of 
prion-induced neurotoxicity and administration of antioxidants such as acetylated hydroxy 
tyrosol effectively extended the survival of prion-diseased mice. One case report suggested 
beneficial effects of neurological disease in a CJD patient that received a complex mixture of 
antioxidants amongst others vitamin E and alpha lipoic acid although he succumbed to 
disease 22 months after onset of symptoms (32).  
A pilot compassionate use trial of doxycycline showed beneficial effects on patient survival 
independent of age, gender and codon 129 polymorphism of the PRNP gene (33). In a first 
of its kind multicentric, prospective, placebo-controlled and randomized Phase II study 
doxycycline did not show superiority in the first interim analysis when compared to placebo 
and the study was stopped (34). Although the latter study provided class 1 evidence that 
doxycycline does not extend survival in prion disease patients, a subsequently published 
case report suggested an unusually long survival time (>5 years) of a patient suffering from 
variably protease-sensitive prionopathy (VPSPr) who was treated with doxycycline (35). 
These reports indicate the helplessness of clinicians who prescribe anti-prion drugs despite 
their proven lack of efficiency. Compound B, IND24 and anle138b were amongst other 
compounds that showed no effect against human prions (34). 
These disappointing results reported above raise questions on the viability of strategies to 
identify prion therapeutics. In particular, it has become evident that cell culture models are 
poorly predictive of effectiveness in vivo. A plausible reason lies in the fact that it is generally 
difficult to maintain prion infectivity in immortalized, continuously growing cells. For such 
cultured cells to remain chronically infected with prions, replication would have to be at least 
as rapid as cell division: a negative differential would inevitably result in loss of infectivity 
over time. In addition, prion replication may impose a fitness cost on infected cells, resulting 
in non-infected cells (which may arise because of inhomogeneously infected cultures or due 
to acquired resistance) overgrowing the system (36). These characteristics lead us to predict 
that infected cell cultures are inherently unstable systems – a prediction verified 
experimentally by the observation that most chronically infected cell lines spontaneously 
gravitate towards lower infectivity titers over time (our unpublished observations). One could 
therefore argue that the crucial issue with N2A cells is not how to cure them, but rather how 
5 | P a g e  
 
to maintain them in an infected state. In this interpretative frame, it is not surprising that 
agents capable of “curing” cultured cells almost always prove entirely ineffective when tested 
in vivo, where brain-resident cells undergo much slower turnover rates and spontaneous 
resistance has hardly any chance to develop (Table 1). 
Cerebellar organotypic cultures slices (COCS) seem to represent a more realistic system for 
testing antiprion compounds, and are indeed gathering a much better record than N2A cells 
in predicting in vivo antiprion efficacy (37-42). The main disadvantage of COCS over N2A 
cells, however, consists in the laboriousness of their production, which precludes their 
feasibility for high-throughput screens. Instead, COCS are best suited as secondary screens 
for intermediate validation of compounds identified in vitro.  
One key consideration in designing an effective therapeutic option is to consider the 
“frangibility” (i.e. the propensity to break) of the pathological protein aggregates. Prion 
aggregate frangibility is the most important parameter in determining prion infectivity; these 
predictions from first principles were largely confirmed in animal models (40). By using “β-
sheet breaking” compounds that convert large aggregates into a larger number of small 
oligomers, one might inadvertently create more propagons (43). It follows that maybe an 
effective therapy should not aspire at breaking down PrPSc aggregates, but rather at 
hyperstabilizing said aggregates (Figure 1). Luminescent conjugated polythiophenes (LCPs) 
appear to act as such prion hyperstabilizers. LCPs bind to cross-β spines in PrPSc (44; 45). 
LCPs can detect PrPSc aggregates with great sensitivity and their emission spectra can 
differentiate between different amyloids (45) and prion strains (46).  
LCPs reduce prion infectivity in samples containing prion aggregates from brains of infected 
mice (47). The binding of the LCPs to amyloid fibrils was resolved at the atomic level and 
was found to rely on cooperative electrostatic interactions. However, digestion with 
proteinase K, which is a proxy for fibril stability, was enhanced by LCPs, whereas infectivity 
of the same prion preparation was decreased dose-dependently (47). These observations 
are consistent with the hypothesis that LCPs indeed decrease the infectivity of prions by 
hyperstabilizing PrPSc aggregates. The structural elucidation of the interaction between LCPs 
and amyloid allowed us to design new LCPs with stronger binding. These showed higher 
efficacy in prolonging the survival of prion-infected mice (48).  
 
Targeting cellular pathways for prion therapy 
The ubiquitin-proteasome system maintains quality control in cells by degrading misfolded or 
damaged proteins (49). Early studies revealed the presence of ubiquitin within protein 
aggregates (50; 51). An elevated level of ubiquitinated proteins in the brains of prion-infected 
mice is associated with a dysfunctional ubiquitin-proteasome system (UPS) (52) which may 
contribute to neurotoxicity. PrPSc can bind to the external leaflet of the 20S proteasomal 
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subunit and may impair its function (53). Other studies have postulated that prion oligomers 
inhibit the catalytic B subunit or prevent the substrate entry into the proteolytic core (54). 
These hypotheses may explain the failure of proteasomes in prion infections (52; 55), but it is 
difficult to conceive how PrP, which resides in the lumen of the endoplasmic reticulum (ER) 
and in the extracellular space, could be driven to encounter proteasomes in the cytosol. The 
idea that PrP undergoes conspicuous endoplasmic-reticulum-associated protein degradation 
(ERAD) is plausible (56; 57) but has been challenged (45).  
Inhibition of USP14, a deubiquitinase attached to the 19S proteasome subunit, results in 
clearance of aggregation-prone proteins (58). A small molecule targeting USP14 accelerates 
the degradation of proteins associated with neurodegenerative diseases such as TDP43, tau 
and ataxin. A yet unexplored strategy targeting misfolded proteins in neurodegenerative 
diseases is generating small molecule compounds, which direct the endogenous E3 ubiquitin 
ligases to their substrates. PROTACS (proteolysis targeting chimeric molecules) consists of 
a peptide which recognizes a specific ubiquitin ligase chemically linked to a small molecule 
that recognizes the target protein (59). Once bound to the target protein, it creates spatial 
proximity between the substrate and ubiquitin ligase, promoting poly-ubiquitination and 
enhanced degradation of the target substrate. Extensive studies were carried out to 
characterize PROTACS for  cancer treatment (60) and perhaps they can be utilized to target 
misfolded prions. A new strategy involves a combination of chaperone proteins and small 
molecule compounds. The small molecule acts as a guide to the substrate whereas the 
chaperone engages with the misfolded proteins and renders it amenable to proteasomal 
degradation (61). Such a strategy was implemented in spinal-bulbar muscular atrophy and 
amyotrophic lateral sclerosis (62). 
 
Targeting the unfolded protein response 
A common event in protein misfolding disorders is the upregulation of unfolded protein 
response (UPR), also referred to as endoplasmic reticulum (ER) stress (63). Over 30% of all 
cellular proteins traverse the ER before being modified and disseminated to their final 
destinations. The ER controls a complex set of cellular processes by which proteins are 
synthesized, folded and postranslationally modified (64). Disturbances in the function of the 
ER affecting may lead to the accumulation of misfolded proteins or alteration in calcium 
homeostasis, resulting in the induction of stress.  
The UPR can restore cellular proteostasis by shutting down global translation and thereby 
reducing the load of misfolded proteins in the ER (65). Also, the UPR enhances the synthesis 
of chaperones and other proteins that assist the protein folding to repair the misfolded 
proteins in the ER (66). The misfolded ER proteins can be retrotranslocated to the cytosol 
where they are degraded by the ERAD pathway (67). The major transducers of UPR are 
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Protein kinase RNA-like ER kinase (PERK), inositol-requiring enzyme-1 (IRE1) and 
activating transcription factor-6 (ATF6). PERK is a transmembrane protein essential for the 
attenuation of the translation by phosphorylation the eukaryotic translation initiation factor 
(eIF2α), whereas IRE1 and ATF6 are mainly involved in the synthesis of chaperones 
necessary for protein folding (68). 
Elevated levels of the ER chaperones GRP94, GRP78 and GRP54 were observed in prion-
infected humans and mice (69). Prion infection leads to disruption in the calcium 
homeostasis in the cell affecting the ER (70); cells exposed to purified PrPSc displayed 
activation of UPR and calcium release from the ER along with the upregulation of 
chaperones identified in CJD patients (70). Furthermore, there exists a complex interplay 
between UPS and ER stress and it is widely believed that inhibition of proteasomal function 
elicits UPR (71).  
Prion-infected mice show sustained activation of PERK and phosphorylation of eIF2α 
resulting in down-regulation of global protein translation through eIF2α phosphorylation (72; 
73), leading to decreased synaptic proteins and neuronal death. Overexpression of the eIF2α 
specific phosphatase GADD34 rescues synaptic defects and neuronal loss, at least for a 
while (73). Pharmacological inhibition of PERK restores translation and provides some 
neuroprotection (73). The ISR inhibitor B (ISRIB), which targets the translational inhibition 
downstream of eIF2α, was also shown to ameliorate prion pathology (74).  
In contrast to PERK inhibitors, Guanabenz and its derivative Sephin 1 prevented 
neurodegeneration in a mouse ALS model by interfering with GADD34 and enhancing the 
phosphorylated status of eIF2α (75). This long-term translational arrest may prevent 
synthesis of new propagons and thereby provide neuroprotection. Guanabenz has previously 
been shown to enhance prion clearance (76), yet severe side effects have restricted its use 
so far. This problem illustrates the basic conundrum of UPR-based therapies: interfering with 
a general control mechanism of translation is inevitably ridden with deleterious, unintended 
consequences (Figure 1). 
 
Targeting Lysosomal degradation and autophagy 
The conversion of PrPC to PrPSc occurs at the plasma membrane (77) and in the endocytic 
pathway, including recycling endosomes and multivesicular bodies (78; 79). The 
accumulation of misfolded prions in the endocytic compartments may alter the composition of 
the vesicular compartments and their functioning. Lysosomes are the major sites for 
degradation of cellular PrPC, and PrPSc can accumulate in lysosomes (80). In cell cultures 
PrPSc can be cleared by lysosomes, however other defects arising in the endolysosomal 
machinery and PrPSc overload may ultimately render lysosomes nonfunctional. Indeed, prion 
8 | P a g e  
 
infection results in reduced levels of membrane-bound rab7, affecting lysosomal maturation 
and their capacity to degrade proteins (81).  
Another key delivery route of PrPSc to lysosomes for degradation is autophagy (82). In 
autophagy the cytosolic constituents are engulfed by a double membrane structure, the 
autophagosome, which fuses with lysosomes releasing its contents for degradation. Giant 
multivesicular bodies and autophagy vesicles (AV) are observed in neurons of prion-infected 
mice, in prion-infected cell cultures, and in genetic prion models (83). Autophagy may play a 
protective role by scooping up aggregates and delivering them for degradation. It was 
originally believed that spongiform vacuoles observed in prion diseases are AVs, yet they do 
not have the membrane characteristics of AVs, nor do they display any autophagy markers. 
Impairing autophagy pharmacologically or by siRNA inhibits the capacity of cells to degrade 
PrPSc (84). Hence, promoters of autophagy and lysosomal degradation could be therapeutic 
against prions (85; 86). Lithium has been shown to enhance the clearance of PrPSc in 
cultured cell lines by inducing autophagy (87), and also slightly reduced cellular PrPC levels. 
Rapamycin and tacrolimus, which also promote autophagy, showed similar results (88; 89). 
Trehalose is an alpha linked disaccharide synthesized by fungi and plants to protect them 
against environmental stress conditions by preventing protein denaturation. In cell culture, 
trehalose induces autophagy and may improve the clearance of misfolded proteins (90). 
PrPSc from prion infected cell cultures was rapidly cleared by treatment with trehalose (91). 
Similarly, imatinib, another autophagy promoting compound, abolished PrPRes levels in cell 
cultures (92). 
 
Chaperone therapy 
Molecular chaperones interact with other proteins and assist them in attaining a stable 
conformation. They represent an important quality control system that prevents misfolding 
and aggregation. In yeast the Hsp104 disaggregase can solubilize cytosolic aggregates of 
Sup35, the yeast prion Ψ (93). A triad of Hsp110/70/40 was identified as a mammalian 
minimal disaggregase (94). Upregulation of Hsp70 alone afforded neuroprotection in model 
systems (95). However, it is unclear whether this triad could be exploited therapeutically 
against prion diseases. 
Chemical chaperones are small molecules that bind to proteins and restore their function by 
refolding them and letting them attain a stable structure. In spite of their non-specific mode of 
action and low affinity, their ability to eliminate protein aggregates makes them attractive as 
therapeutics. Methyl amines and glycerol have been effective in blocking the conversion of 
PrPC to PrPSc in cell culture models (96). Also anthracyclines, porphyrins and diazo dyes 
were also effective in blocking prion replication in the in vitro assays (97), yet in vivo results 
were discouraging. 
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Active immunotherapy against prion disease 
Immunization strategies have shown promise in various protein misfolding disorders (98). 
Active immunization against prions is hindered by the widespread expression of the cellular 
prion protein PrPC in the body, leading to self-tolerance. Immunization with small prion 
fragments designed to fit into known grooves of major histocompatibility complex II (MHC-II) 
binding pockets elicited anti-PrPC immunity and antibodies derived thereof reduced 
Proteinase K-resistant PrPSc levels in a prion-infected tumor transplant (99). Active 
immunization of mice with recombinant prion protein in mice delayed prion disease when the 
immunogen was administered prophylactically and, to a lesser extent, when animals were 
already infected (100). Clinical disease induced through orally administered prions was 
attenuated after vaccination of mice (101; 102) and deer (103). However, another report 
failed to show differences in disease susceptibility through prophylactic prion vaccination in 
deer suffering from chronic wasting disease (CWD), a prion disease of deer and elk (104). A 
modest disease delay was achieved after immunization with recombinant prion protein 
fragments and intraperitoneal prion inoculation (105; 106). Attempts to break self-tolerance 
using a combined DNA and protein vaccination regime yielded mixed results (107; 108).  
Because the immune system is tolerant to self-antigens, antibodies derived from 
immunizations often lack the affinity needed for effective therapy. Addressing the molecular 
whereabouts of PrPC self-tolerance, one study found that even small amounts of 
extraneuronal PrPC abolished an efficient immune response (109). A delay in disease onset 
was achieved by Freund’s adjuvant, suggesting a benefit through an unspecific activation of 
the immune system (110). Another study suggested a strongly neuroprotective effect through 
post-hoc immunostimulation against prions using repetitive administration of CpG 
oligodeoxynucleotides (CpG-ODN) that are suggested to stimulate innate immunity (111). A 
chronic CpG-ODN treatment, however, was shown to induce profound immunosuppression 
with lymphoid follicle destruction, hepatotoxicity and hemorrhagic ascites (112). Moreover, 
repetitive immunization of mice and increases their susceptibility to peripherally induced 
prion disease through reduced prion clearance and/or size of follicular dendritic cells (FDCs) 
networks suggesting that individual immune states, e.g. hyperactivated or depressed, may 
predispose to prion disease vulnerability (113). 
 
Passive immunotherapy against the prion protein 
The first proof-of-concept for prion immunotherapy demonstrated a reduction in prion 
infectivity through exposure of cell-free, purified prions with PrP-specific antisera (114). 
Passive prion immunotherapy through diminishing PrPSc levels in vitro was exhibited when 
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the monoclonal anti-PrP antibodies 6H4, SAF32, SAF61 or Fab-fragments of the PrP-specific 
antibodies D13, D18, R1 and R2 were given to chronically prion infected N2A neuroblastoma 
cells (115-118). When D13 was given as a bivalent antibody (D13-IgG), widespread neuronal 
apoptosis was observed suggesting neuronal death through cross-linking of PrPC, a finding 
that was not seen with the holo-IgG molecule of D18 (119). When a single-chain fragment 
(scFv) of D18 was engineered into the adeno-associated virus 9 (AAV9) vector and 
transduced into RML-infected mice brains, prolonged survival of inoculated mice was 
observed (120). The toxic effects of D13 were reproduced in a second study (41).  
Transgenic overexpression of an IgMa µ chain of the anti-PrP antibody 6H4 reduced prion 
infectivity and levels of PrPSc in prion-infected mice (121), and peripheral injections with the 
monoclonal anti-PrP antibodies 8B4, 8H4 and 8F9 led to a decrease in clinical disease onset 
(122), as were injections with the PrP-α1 helix targeting antibody 31C6 (123). 31C6 was 
reported to be protective against prion disease when given as late as clinical signs had 
already manifested, albeit through intraventricular application (124).  
The safety profile of the anti-PrP antibodies ICSM18 and ICSM35 is highly controversial 
(125). One report stated no drug-related toxicity in mice of both compounds after stereotaxic 
injections of 2 µg of antibody (126). However, in a dose-escalation study with ICSM18, the 
allegedly safe dosage of 2 µg of antibody already showed drug-attributable neurotoxic effects 
raising concerns about the suitability of ICSM18 to clinical trials (127). Of note, POM1 is a 
monoclonal antibody directed against a similar epitope as ICSM18 shows severe 
neurotoxicity ex vivo and in vivo (39; 41; 128; 129). 
Human autoantibodies recognizing the mutant prion fragment PrPA117V106-126 from 
commercially available, pooled immunoglobulins were proposed to be protective against 
PrPA117V106-126-induced neuronal death in vitro through microglial uptake of the mutated 
fragment (130; 131). However PrPA117V106-126 does not exist in nature, and therefore such 
speculations are implausible.  
When the octapeptide repeat domain of the prion protein (OR) at its N-terminus was targeted 
in prion-infected mice through intraventricular delivery of the anti-PrPC-OR antibody 4H11, no 
disease amelioration was observed (132). Instead, 4H11-injected animals showed behavioral 
deficits and heightened neuronal loss and astrogliosis (132). Because the N-terminus of PrP 
is crucial for neurotoxicity, (39; 41), it will be important to investigate the differences between 
4H11 and  which was shown to be safe when given intracerebrally in doses up to 6 µg (41). 
 
Targeting the peripheral replication and neuroinvasion of prions 
Genetic blockade of B-cell maturation ablated the onset of prion disease after peripheral 
prion inoculation (133). In the light of these findings one might speculate that 
pharmacological ablation of B-cells, e.g. through the anti-CD20 antibody rituximab, could 
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afford post-exposure prophylaxis. Initial prion accumulation occurs in secondary lymphoid 
organs prior to neuroinvasion (134) whereas other prion strains, so-called “neurotropic” 
prions, can primarily invade the central nervous system without the need of peripheral 
replication (135). Early studies have argued for the requirement of mature PrPC-expressing 
follicular dendritic cells (FDCs) for prion neuroinvasion: ablation of differentiated B-cells 
prevented peripheral scrapie pathogenesis due to the lack of FDC maturation signals 
secreted by B-cells (133) and mice lacking either expression of PrPC on mature FDCs or 
lacking mature FDCs did not succumb to peripherally initiated prion disease (136). As FDCs 
depend on lymphotoxins and tumor necrosis factor from B-cells for development and 
maintenance, they provide an opportunity to target prion replication (137). Administration of a 
hybrid protein consisting of lymphotoxin β receptor and human immunoglobulin (LTβR-Ig) 
dedifferentiated FDCs through inhibition of the lymphotoxin α/β pathway and led to a delay of 
prion disease upon peripheral inoculation (138), even when LTβR-Ig was given late during 
the disease course – but not upon intracerebral inoculation (139). Dedifferentiation of FDCs 
through a single injection of soluble human TNF receptor linked to the Fc portion of human 
immunoglobulin IgG1 (huTNFR:Fc) also showed a decreased disease susceptibility to 
peripherally adminstered prions (140).  
FDCs trap immune complexes through binding to Fcγ receptors. They also bind opsonized 
antigens via the complement receptors CD21/CD35. Pharmacological and genetic ablation of 
the complement factor C3 or its receptor CD21/CD35 prolonged incubation times in 
peripherally prion-inoculated mice (141; 142). Hence, complement activation through PrPSc 
may lead to more FDC-bound PrPSc and hence favor prion replication. Neither membrane-
bound nor secreted immunoglobulins did alter prion neuroinvasion (142). Circulating immune 
complexes bound to PrPSc may not play a role in prion pathology since deletion mutants of a 
variety of Fcγ receptors had no effect on prion incubation times (142).  
The sympathetic nervous system (SNS) innervates secondary lymphoid organs and 
experimental evidence pointed towards an involvement of the SNS in prion pathogenesis as 
splanchnic nerves are an early replication site after peripheral prion inoculation (143) and 
accumulation of prions was found in sympathetic and sensory ganglia as well (144). A 
transient pharmacological ablation of the SNS through injection of 6-hydroxydopamine (6-
OHDA) or anti-nerve-growth factor antibodies (anti-NGFAb) led to delayed scrapie onset 
after peripheral inoculation (145).  
In a study addressing the cells responsible for conveying prions to the gut-associated 
lymphoid tissue (GALT) after oral exposure, microfold cells (M-cells) (146), specialized 
epithelial cells, were depleted through application of a monoclonal antibody against receptor 
activator of NF-κB ligand (RANKL) (147). M-cell depletion led to a reduced prion uptake into 
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FDCs without modifying FDC status and prevented disease onset after oral prion exposure 
(147).  
 
Therapies against prion disease in humans 
To date, no clinical trial against prion diseases has succeeded. One inherent limitation of this 
rare disease concerning double-blind, randomized controlled multicenter trials on large 
patient groups is the low prevalence of prion diseases. Rare diseases are less likely to be 
funded through industry, and indeed a systemic review found only one out of seven trials in 
CJD to have an industrial sponsor in contrast to an overall average of three out of four 
industry-sponsored studies (148; 149).  
Due to the lack of a prion disease-specific disease rating scale, initial clinical studies were 
performed using cognitive test batteries not specifically designed to address prion disease 
phenotypes (27) or using survival as outcome measure (150). Limited sample sizes and 
heterogeneous endpoints lead to therapeutic interventions being published as case reports. 
Yet case reports are intrinsically flawed by publication bias: an exceptional treatment 
success is more likely to be published than a treatment failure. Extension of the endpoint-
based primary outcome, i.e. survival, in prion disease trials towards neuropsychological, 
psychiatric and other functional ranking systems may improve power calculations for future 
trials (151).  
 
Palliative care in prionopathies 
With currently no effective therapy available against prion diseases, all medical care is 
essentially supportive and palliative. Primarily, nursing efforts are laid out to keep the 
patients safe, i.e. by providing walking assistance through walkers and wheelchairs and – 
during the terminal stage – a hospital bed with regular skin and mouth care and assistance 
during food intake (152). Specifically, pyrexia, i.e. broad variations in body temperature was 
suggested to be a common symptom which, if left untreated, may lead enhanced agitation 
that could be alleviated through the use of fans and tepid sponge baths (153). Further 
distressing symptoms that need to be addressed carefully are myoclonic jerking, heightened 
sensory sensitivity, shortness of breath, incontinence and constipation (153).  
Strict preventive measures in agriculture and in human medicine have reduced the incidence 
of variant Creutzfeldt-Jakob’s disease to a near complete disease extinction (154). Although 
the current WHO Tables on Tissue Infectivity Distribution in Transmissible Spongiform 
Encephalopathies (155) does not formally deem blood or urine from non-vCJD diseased 
patients as infectious, some reports suggest detectable infectivity of urine from sCJD patients 
and transmissibility of blood from human gPrD patients to primates (156; 157). Hence, 
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preventive actions have to be followed by all personnel working with non-vCJD prionopathies 
as well, including but not limited to wearing appropriate protective gear and gaining 
knowledge about the relative infectivity of different human tissues (158). On another note, as 
CJD patients need both palliative and mental health care, it was suggested that the 
development of multidisciplinary guidelines can improve patient care through the 
development of sophisticated treatment schemes (159).  
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Figure Legends 
 
Figure 1: Upon encountering a prion propagon, the cellular PrPC is converted and 
incorporated into PrPSc. The conversion of PrPC to PrPSc probably begins on the plasma 
membrane and continues throughout the endocytic pathway. PrP aggregates were also 
observed in the cytoplasm and may originate through ERAD and/or leakage from defective 
endosomes and lysosomes. Potential therapeutic points of intervention include prion 
clearance (antibody therapy) and prion replication, including hyperstabilization of aggregates. 
Intracellular targets include enhancers of autophagy and of lysosomal function, as well as 
modulators of the UPS and chemical chaperones.  
 
Figure 2: Immunotherapy is quickly evolving as an attractive therapeutic strategy against 
prion disease. The monoclonal antibody POM2 binds to a degenerate epitope in the 
octoapeptide repeat region of PrPC and protects against prion-induced neurodegeneration. 
The red dots indicate the N terminus of prion protein, also called the flexible tail (FT), which 
is intrinsically disordered. The ordered globular domain (GD) of PrPC is represented in 
magenta. The interaction between a F(ab)1 fragment of the POM2 antibody (cyan and grey 
structures) and its cognate epitope on PrPC (depicted in cyan) is visualized in the blow-up. 
Solid lines (blue) indicate the interactions. 
 
